Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and  emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

• For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
• What is the optimal therapy for a patient with del(17p) CLL?
• When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
• What are best practices in the use of BTK inhibitors for patients with MCL?
• How can BTK inhibitor resistance occur?
• How might investigational noncovalent BTK inhibitors be used should they be approved?
• What are key adverse events with BTK inhibitors?

Presenters:

Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology 
Willamette Valley Cancer Institute
Eugene, Oregon 

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5. 

Link to full program:
https://bit.ly/3NEpsYQ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.